Given that PD-L1 expression may predict the response to anti-PD-1/PD-L1 monoclonal antibodies in endometrial cancer, further research is required to investigate whether the presence of either characteristic signals a higher likelihood of a favorable response if immunotherapy is administered. This evidence concerns the gene PDCD1 and endometrial cancer.